Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study.
Adsorption
Intoxication
MDMA
Multi-organ failure
Journal
Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149
Informations de publication
Date de publication:
15 Jun 2020
15 Jun 2020
Historique:
received:
20
04
2020
accepted:
31
05
2020
entrez:
17
6
2020
pubmed:
17
6
2020
medline:
17
6
2020
Statut:
epublish
Résumé
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") abuse is frequent, and overdosing might cause severe and eventually lethal multi-organ failure. To date, there is no causal therapy of MDMA intoxication and removal of MDMA from the circulation might be a reasonable measure to prevent adverse courses after overdosing. We present here first-in-man experience and in vitro data supporting a potential role of an adsorber device in severe MDMA overdosing. We applied a CytoSorb adsorber device in a 21-year-old male presenting with severe MDMA intoxication and multi-organ failure, including neurological impairment, hyperpyrexia, rhabdomyolysis, oliguric renal failure, liver failure, and coagulopathy with disseminated gastrointestinal and intramuscular bleeding. Use of the adsorber device was associated with a decline in MDMA concentrations in serum from 540 to 140 ng/ml within the first 24 h, a decrease of interleukin 6 and myoglobin levels, and subsequent clinical improvement. The patient was discharged from hospital after restoration of organ function and full neurological recovery. Effective elimination of MDMA by the adsorber device could be confirmed in vitro, when the device lowered MDMA concentrations to non-detectable levels. We report here first-in-man experience and in vitro data showing the capacity of a CytoSorb adsorber device for MDMA removal. Early integration of CytoSorb use may enhance the management of severe MDMA intoxication, though we cannot prove whether clinical improvement was directly related to elimination of MDMA or beneficial effects on rhabdomyolysis, hyperinflammation, or liver failure. Our findings encourage further investigation of the CytoSorb adsorber device in a prospective study and to evaluate its use for other intoxications.
Sections du résumé
BACKGROUND
BACKGROUND
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") abuse is frequent, and overdosing might cause severe and eventually lethal multi-organ failure. To date, there is no causal therapy of MDMA intoxication and removal of MDMA from the circulation might be a reasonable measure to prevent adverse courses after overdosing. We present here first-in-man experience and in vitro data supporting a potential role of an adsorber device in severe MDMA overdosing.
RESULTS
RESULTS
We applied a CytoSorb adsorber device in a 21-year-old male presenting with severe MDMA intoxication and multi-organ failure, including neurological impairment, hyperpyrexia, rhabdomyolysis, oliguric renal failure, liver failure, and coagulopathy with disseminated gastrointestinal and intramuscular bleeding. Use of the adsorber device was associated with a decline in MDMA concentrations in serum from 540 to 140 ng/ml within the first 24 h, a decrease of interleukin 6 and myoglobin levels, and subsequent clinical improvement. The patient was discharged from hospital after restoration of organ function and full neurological recovery. Effective elimination of MDMA by the adsorber device could be confirmed in vitro, when the device lowered MDMA concentrations to non-detectable levels.
CONCLUSIONS
CONCLUSIONS
We report here first-in-man experience and in vitro data showing the capacity of a CytoSorb adsorber device for MDMA removal. Early integration of CytoSorb use may enhance the management of severe MDMA intoxication, though we cannot prove whether clinical improvement was directly related to elimination of MDMA or beneficial effects on rhabdomyolysis, hyperinflammation, or liver failure. Our findings encourage further investigation of the CytoSorb adsorber device in a prospective study and to evaluate its use for other intoxications.
Identifiants
pubmed: 32542550
doi: 10.1186/s40635-020-00313-3
pii: 10.1186/s40635-020-00313-3
pmc: PMC7295925
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Références
J Clin Pharmacol. 2014 Mar;54(3):245-52
pubmed: 24431106
Ther Hypothermia Temp Manag. 2018 Sep;8(3):173-175
pubmed: 29694265
Intensive Care Med. 2019 Feb;45(2):236-239
pubmed: 30446798
Ther Drug Monit. 2008 Jun;30(3):320-32
pubmed: 18520604
Ther Drug Monit. 2004 Apr;26(2):137-44
pubmed: 15228154
Front Cardiovasc Med. 2019 Jun 04;6:71
pubmed: 31275944
Crit Care Med. 2004 Mar;32(3):801-5
pubmed: 15090965
Euro Surveill. 2013 May 30;18(22):
pubmed: 23787082
Crit Care Resusc. 1999 Dec;1(4):368-70
pubmed: 16599881
PLoS One. 2019 Apr 26;14(4):e0215823
pubmed: 31026303
Acta Pharm Nord. 1991;3(1):9-14
pubmed: 1677250
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Heart Lung. 2014 Mar-Apr;43(2):117-9
pubmed: 24373952
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Blood Purif. 2002;20(4):380-8
pubmed: 12169849
Crit Care. 2011;15(1):205
pubmed: 21371356
Blood Purif. 2019;48(3):196-202
pubmed: 31039564
ASAIO J. 2013 Mar-Apr;59(2):99-106
pubmed: 23438770
Eur Neuropsychopharmacol. 2015 Oct;25(10):1637-49
pubmed: 26073279
J Intensive Care Med. 2013 Jul-Aug;28(4):252-8
pubmed: 22640978
J Med Case Rep. 2014 Jun 18;8:204
pubmed: 24942782
J Emerg Nurs. 2015 Sep;41(5):447-50
pubmed: 26078261